EGFR and non-small cell lung carcinoma: In 2016, the FDA approved the ctDNA assay Cobas®EGFR Mutation Test v2 (Roche Diagnostics) for detection of EGFR mutations in NSCLC patients as a companion diagnostic to the EGFR inhibitor erlotinib.